ArticleBMJ open2020

Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial.

Julien Hogan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.